Centre Catalan d'Oncologie

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Lung cancer6 trials
• Metastatic breast cancer3 trials
• Pancreatic cancer2 trials
• Bladder cancer1 trial
• Colorectal cancer1 trial
• Liver and biliary tract cancer1 trial
• Prostate cancer1 trial

Phase

• Phase 23 trials
• Phase 33 trials

Status

• Active, not recruiting7 trials
• Recruiting3 trials
• Completed1 trial

Lead sponsor

• UNICANCER4 trials
• Hoffmann-La Roche2 trials
• Institut du Cancer de Montpellier - Val d'Aurelle2 trials
• European Organisation for Research and Treatment of Cancer - EORTC1 trial
• GFPC Investigation1 trial
• and 1 more

Running trials

• Recruiting

  Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)

  NCT07243132· GFPC Investigation· Source

  Contact: Sabine VEILLIOT

• Recruiting

  PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)

  NCT04790253· European Organisation for Research and Treatment of Cancer - EORTC· Source

  Contact: EORTC Reception

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

  NCT05296798· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients

  NCT05065801· Phase 2· Institut du Cancer de Montpellier - Val d'Aurelle· Source

• Recruiting

  Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

  NCT04570943· Phase 2· Institut du Cancer de Montpellier - Val d'Aurelle· Source

• Active, not recruiting

  Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE)

  NCT05049044· Groupe Francais De Pneumo-Cancerologie· Source

• Active, not recruiting

  Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases

  NCT03143322· UNICANCER· Source

• Active, not recruiting

  PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer

  NCT03774732· Phase 3· UNICANCER· Source

• Completed

  PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection

  NCT03079011· Phase 3· UNICANCER· Source

• Completed

  Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients

  NCT02980510· Phase 2· UNICANCER· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer2 recruiting
• Pancreatic cancer1 recruiting

Closed trials

• Completed

  A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

  NCT03782207· Hoffmann-La Roche· Source